SuperworthOpus Genetics EPS IRD
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- −$1.35
- Latest quarter, Q2 FY26
- −$0.14
- Fiscal year 2025
- −$0.82
Opus Genetics' earnings per share was −$1.35 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.14.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.82 | n/a |
| FY2024 | −$2.04 | n/a |
| FY2023 | −$0.48 | −163% |
| FY2022 | $0.76 | n/a |
| FY2021 | −$4.69 | n/a |
| FY2020 | −$5.08 | n/a |
| FY2019 | −$8.76 | n/a |
| FY2018 | −$21.36 | n/a |
| FY2017 | −$49.92 | n/a |
| FY2016 | −$19.68 | n/a |
| FY2015 | −$38.40 | n/a |
| FY2014 | −$52.80 | n/a |
| FY2013 | −$38.40 | n/a |
| FY2012 | −$28.80 | n/a |
| FY2011 | −$62.40 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.14 | n/a | −$1.35 | |
| Q1 FY26 | −$0.75 | n/a | −$1.33 | |
| Q4 FY25 | −$0.21 | n/a | −$0.82 | |
| Q3 FY25 | −$0.25 | n/a | −$1.77 | |
| Q2 FY25 | −$0.12 | n/a | −$1.81 | |
| Q1 FY25 | −$0.24 | n/a | −$1.99 | |
| Q4 FY24 | −$1.16 | n/a | −$2.04 | |
| Q3 FY24 | −$0.29 | −216% | −$1.09 | |
| Q2 FY24 | −$0.30 | n/a | −$0.55 | |
| Q1 FY24 | −$0.29 | n/a | −$0.49 | |
| Q4 FY23 | −$0.21 | −113% | −$0.48 | |
| Q3 FY23 | $0.25 | n/a | $1.31 |
Against its peers
Companies in Drug Manufacturers - General nearest Opus Genetics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| IRDOpus Genetics | −$1.35 | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| ABUSArbutus Biopharma | $0.78 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| LFVNLifevantage | $0.40 | −46% a year |
| Peer median | $0.85 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Opus Genetics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.